Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis. Remicade has also been granted orphan drug status for Kawasaki disease in Japan.
TABLE OF CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Remicade : Crohn’s disease
23 Remicade : Axial spondyloarthritis (axSpA)
35 Remicade : Rheumatoid arthritis (RA)
47 Remicade : Psoriatic arthritis (PsA)
59 Remicade : Ulcerative colitis
74 Remicade : Psoriasis
LIST OF FIGURES
14 Figure 37: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
16 Figure 19: Datamonitor Healthcare’s drug assessment summary of Humira in Crohn’s disease
19 Figure 6: Sales of filgotinib and upadacitinib across the US, Japan, and five major EU markets, by drug, 2016–25
26 Figure 20: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
27 Figure 2: Datamonitor Healthcare’s drug assessment summary of Alofisel in Crohn’s disease
31 Figure 18: Remicade for Crohn’s disease – SWOT analysis
53 Figure 3: Datamonitor Healthcare’s drug assessment summary of Alofisel in Crohn’s disease
54 Figure 6: Entyvio for Crohn’s disease – SWOT analysis
68 Figure 8: Humira for Crohn’s disease – SWOT analysis
69 Figure 24: Datamonitor Healthcare’s drug assessment summary of Tysabri in Crohn’s disease
80 Figure 11: Remicade for Crohn’s disease – SWOT analysis
81 Figure 33: Filgotinib for Crohn’s disease – SWOT analysis
LIST OF TABLES
7 Table 1: Remicade drug profile
9 Table 2: Remicade pivotal trial data in adult Crohn’s disease
13 Table 3: Remicade pivotal trial data in pediatric Crohn’s disease
20 Table 4: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
23 Table 5: Remicade drug profile
26 Table 15: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
32 Table 7: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
36 Table 8: Remicade drug profile
40 Table 9: Remicade late-phase trial data in rheumatoid arthritis
48 Table 10: Remicade drug profile
50 Table 11: Remicade pivotal trial data in psoriatic arthritis
60 Table 12: Remicade drug profile
62 Table 13: Remicade pivotal trial data in ulcerative colitis
75 Table 14: Remicade drug profile
77 Table 15: Remicade pivotal trial data in psoriasis
78 Table 16: Remicade ongoing late-phase clinical trials in psoriasis
79 Table 25: Etrolizumab drug profile
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!